Why Rocket Pharmaceuticals Could Be the Underdog Gem in Biotech Stocks
Rocket Pharmaceuticals targets transformative gene therapies for rare diseases like Danon disease and Fanconi Anemia. The RP-A501 treatment shows promising Phase 2 results, with a major update expected in the first half of 2025. Rocket has a strategic cash allocation of $372.3
